Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Safety and efficacy of risedronate for patients with esophageal varices and liver cirrhosis: a non-randomized clinical trial

Full text
Author(s):
Lima, Talles Bazeia [1] ; Amaral Santos, Livia Alves [1] ; de Carvalho Nunes, Helio Rubens [2] ; Silva, Giovanni Faria [1] ; Caramori, Carlos Antonio [1] ; Qi, Xingshun [3] ; Romeiro, Fernando Gomes [1]
Total Authors: 7
Affiliation:
[1] Sao Paulo State Univ UNESP, Gastroenterol Div, Internal Med Dept, Botucatu Med Sch, Sao Paulo, SP - Brazil
[2] Sao Paulo State Univ UNESP, Botucatu Med Sch, Publ Hlth Dept, Sao Paulo, SP - Brazil
[3] Gen Hosp Shenyang Mil Command, Sheng, Liaoning - Peoples R China
Total Affiliations: 3
Document type: Journal article
Source: SCIENTIFIC REPORTS; v. 9, DEC 12 2019.
Web of Science Citations: 0
Abstract

Despite the high prevalence of osteoporosis in liver cirrhosis, the indication of bisphosphonates for patients with esophageal varices has been avoided due to risk of digestive mucosal damage. Therefore, this study aimed to evaluate the safety profile of risedronate treatment for patients with osteoporosis, liver cirrhosis and esophageal varices with low risk of bleeding. A total of 120 patients were allocated into two groups according to their bone mineral density measured by dual-energy X-ray absorptiometry. In the intervention group, 57 subjects with osteoporosis received oral risedronate at 35 mg weekly plus daily calcium and vitamin D supplementation. In the control group, 63 subjects with osteopenia received only calcium and vitamin D. The groups received the treatment for one year and underwent surveillance endoscopies at six and 12 months, as well as a control dual-energy X-ray absorptiometry after a 12-month follow-up. The study received Institutional Review Board approval. The groups had not only comparable Model for End-stage Liver Disease score and esophageal varices degree, but also similar incidence of digestive adverse effects. A significant improvement was achieved in the intervention group in the lumbar spine T score (p < 0.001). The results suggest that risedronate may be safely used in liver cirrhosis and esophageal varices with low bleeding risk under endoscopic surveillance, thus allowing bone mass recovery. (AU)

FAPESP's process: 14/22572-9 - Bone changes in patients with liver cirrhosis treated for osteoporosis and osteopenia
Grantee:Lívia Alves Amaral Santos
Support Opportunities: Scholarships in Brazil - Doctorate
FAPESP's process: 16/07117-9 - Risedronate for osteoporosis treatment in patients with liver cirrhosis and esophageal varices: assessment on safety profile and bone mass
Grantee:Fernando Gomes Romeiro
Support Opportunities: Regular Research Grants